Trials / Completed
CompletedNCT02082210
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
A Phase 1b/2 Study of Ramucirumab in Combination With LY2875358 in Patients With Advanced Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 97 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find a recommended schedule and dose range for Emibetuzumab when given with ramucirumab that may be safely given to participants with cancer. In Part A of this study, escalating doses of Emibetuzumab will be given in combination with a fixed dose of ramucirumab to evaluate the safety of the combination. After a recommended schedule and dose range of Emibetuzumab and ramucirumab has been established, Part B of the study will confirm safety and to see how well certain tumors respond to the combination of study drugs. The average amount of time on study is expected to be about 6 months.
Conditions
- Advanced Cancer
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Hepatocellular Cancer
- Renal Cell Carcinoma
- Non-Small Cell Lung Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Emibetuzumab | Administered Intravenously (IV) |
| DRUG | Ramucirumab | Administered Intravenously (IV) |
Timeline
- Start date
- 2014-03-07
- Primary completion
- 2017-12-05
- Completion
- 2018-01-24
- First posted
- 2014-03-10
- Last updated
- 2020-12-19
- Results posted
- 2020-12-19
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02082210. Inclusion in this directory is not an endorsement.